In the BioHarmony Drug Report Database

"Preview" Icon

Osimertinib

Tagrisso (osimertinib) is a small molecule pharmaceutical. Osimertinib was first approved as Tagrisso on 2015-11-13. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. It is known to target epidermal growth factor receptor. Tagrisso’s patent is valid until 2035-01-02 (FDA).

 

Trade Name

 

Tagrisso
 

Common Name

 

osimertinib
 

ChEMBL ID

 

CHEMBL3353410
 

Indication

 

non-small-cell lung carcinoma
 

Drug Class

 

Tyrosine kinase inhibitors: epidermal growth factor receptor (EGFR) inhibitors

Image (chem structure or protein)

Osimertinib structure rendering